Article published in Urologia Polska 1996/49/2.

authors

Andrzej Borkowski: Katedra i Klinika Urologii A.M. w Warszawie
Kierownik Kliniki: prof. dr hab. med. Andrzej Borkowski

keywords

advanced prostate cancer treatment prognosis

references

1. Alisun D.L., Whelan P: Palliative management of hormone insensitive prostatic can-
cer. Eur. Urol. Update Series. EBU 1994, 3.
2. Crawford ED., De Antonioni E.P: Combined androgen blockade: an idea whose
time has come. Proceedings of 4th Intern. Symposium on recent advances in urologi-
cal cancer diagnosis and treatment. SCI, Paris, str.260.
3. Denis L, Newling D.W., Whelan P., Bono A., Syhester R., Vermeylen K., EORTCGU
Group: Abstracts of Xith Congres of EAU. Berlin 1994, abstr. 23.
4. Eorcade R.O.: Is it still justified to withold hormonal treatment until symptoms are
bothersone? Proceedings of 4th International Symposium on recent advances in uro-
logical cancer diagnosis and treatment. Paris 1994, SCI, 300.
5. Frohmiiller H., Theiss M., Wirth MP: Radical prostatectomy for carcicoma of the
prostate: Long-term follow up of 115 patients. Eur. Urol., 1991, 19, 279.
6. Haillot O., Yillers A.: Cancer de prostate: cxperience et opinions de T.A. Stamey
(Stanfors) sur l'histoire naturelle, les marges de resection positives et la place de la
radiotherapie (I). Progres en Urologie, 1995, 5, 195.
7. Khoury S.: Hormone resistant prostatic cancer. Proceedings of 4th International Sym-
posium on recent adiwances in urological cancer diagnosis and treatment. SCI, Pa-
ris, 1994, 395.
8. Matzkin H., Perito P.E., Soloway M.S.: Prognostic factors in metastatic prostate can-
cer. Cancer, 1993, 72. Suppl. 3788.
9. Newling D.W., On behalf of European/Australian co-operative group.: The response
of advances prostatic cancer to a new non steroidal antiandrogen: results of a multi-
center open phase II study of Casodex. Eur. Urol., 1990, 18 (suppl. 3), 18.
10. Newling D.W., Denis L., Vermeylen K. EORTC-GU Group: Orchidectomy versus
Goserelin and Flutamide in the treatment of newly diagnosed mateastatic prostate
cancer. Cancer, 1993, 72, 3793.
11. Schmiedt J.D., Johnson D.E., Scott W.W., Gibbons PR., Prout GR., Murphy G.P.:
Chemotherapy of advanced prostatic cancer. Urology, 1976, 7, 602.
12. Soloway M.: Prognostic factors in metastatic prostate cancer. Symposium on thera-
peutic advances in prostate cancer. AUA, San Antonio 1993.
13. Zincke H.: Radical prostatectomy in patients with clinical T2c, T3, and pathologic N+ adenocarcinoma of the prostate. Proceedings of 4th International Symposium on recent advances in urological cancer. Diagnosis and treatment. SCI, Paris, 1994, 237.